{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T04:24:07Z","timestamp":1787113447119,"version":"build-2736575974"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,18]]},"DOI":"10.7759\/cureus.114764","type":"journal-article","created":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T03:33:15Z","timestamp":1787110395000},"source":"Crossref","is-referenced-by-count":0,"title":["Bridging the Gap Between Regulatory Approval and Patient Access: The Case for Insurance Coverage of Approved Allogeneic Stem Cell Therapy in Knee Osteoarthritis"],"prefix":"10.7759","author":[{"given":"Amit Kumar","family":"Agarwal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gautam","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pradeep","family":"Aggarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajashekar","family":"Danda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(23)00163-7","article-title":"Global, regional, and national burden of osteoarthritis, 1990-2020 and projections to 2050: a systematic analysis for the Global Burden of Disease Study 2021","volume":"5","year":"2023","unstructured":"Global, regional, and national burden of osteoarthritis, 1990-2020 and projections to 2050. a systematic analysis for the Global Burden of Disease Study 2021. Lancet Rheumatol. 2023, 5:e508-22. 10.1016\/S2665-9913(23)00163-7","journal-title":"Lancet Rheumatol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000041335","article-title":"Recent advances in osteoarthritis research: a review of treatment strategies, mechanistic insights, and acupuncture","volume":"104","author":"Lou Z","year":"2025","unstructured":"Lou Z, Bu F. Recent advances in osteoarthritis research: a review of treatment strategies, mechanistic insights, and acupuncture. Medicine (Baltimore). 2025, 104:e41335. 10.1097\/MD.0000000000041335","journal-title":"Medicine (Baltimore)"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ocarto.2024.100497","article-title":"Non-pharmacological and non-surgical interventions to manage patients with knee osteoarthritis: an umbrella review 5-year update","volume":"6","author":"Ferreira RM","year":"2024","unstructured":"Ferreira RM, Martins PN, Gon\u00e7alves RS. Non-pharmacological and non-surgical interventions to manage patients with knee osteoarthritis: an umbrella review 5-year update. Osteoarthr Cartil Open. 2024, 6:100497. 10.1016\/j.ocarto.2024.100497","journal-title":"Osteoarthr Cartil Open"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1177\/03635465231180323","article-title":"Efficacy and safety of Stempeucel in osteoarthritis of the knee: a phase 3 randomized, double-blind, multicenter, placebo-controlled study","volume":"51","author":"Gupta PK","year":"2023","unstructured":"Gupta PK, Maheshwari S, Cherian JJ, et al.. Efficacy and safety of Stempeucel in osteoarthritis of the knee: a phase 3 randomized, double-blind, multicenter, placebo-controlled study. Am J Sports Med. 2023, 51:2254-66. 10.1177\/03635465231180323","journal-title":"Am J Sports Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ocarto.2025.100723","article-title":"Two years efficacy and safety outcomes of using allogeneic, pooled mesenchymal stromal cells for osteoarthritis of knee in a double-blind randomized placebo-controlled phase 3 study","volume":"8","author":"Gupta PK","year":"2026","unstructured":"Gupta PK, Maheshwari S, Cherian JJ, et al.. Two years efficacy and safety outcomes of using allogeneic, pooled mesenchymal stromal cells for osteoarthritis of knee in a double-blind randomized placebo-controlled phase 3 study. Osteoarthr Cartil Open. 2026, 8:100723. 10.1016\/j.ocarto.2025.100723","journal-title":"Osteoarthr Cartil Open"},{"key":"ref6","unstructured":"Cipla partners with Stempeutics, launches stem cell therapy for knee osteoarthritis. (2025). Accessed. May 27, 2026: https:\/\/www.cipla.com\/press-releases-statements\/cipla-partners-stempeutics-launches-stem-cell-therapy-knee-osteoarthr...."},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1002\/ksa.70001","article-title":"The use of injectable orthobiologics for knee osteoarthritis: a formal ESSKA-ORBIT consensus. Part 2-cell-based therapy","volume":"33","author":"de Girolamo L","year":"2025","unstructured":"de Girolamo L, Filardo G, Abat F, et al.. The use of injectable orthobiologics for knee osteoarthritis: a formal ESSKA-ORBIT consensus. Part 2-cell-based therapy. Knee Surg Sports Traumatol Arthrosc. 2025, 33:4079-95. 10.1002\/ksa.70001","journal-title":"Knee Surg Sports Traumatol Arthrosc"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.4103\/ijmr.IJMR_1842_15","article-title":"Preclinical safety and toxicity evaluation of pooled, allogeneic human bone marrow-derived mesenchymal stromal cells","volume":"144","author":"Rengasamy M","year":"2016","unstructured":"Rengasamy M, Gupta PK, Kolkundkar U, et al.. Preclinical safety and toxicity evaluation of pooled, allogeneic human bone marrow-derived mesenchymal stromal cells. Indian J Med Res. 2016, 144:852-64. 10.4103\/ijmr.IJMR_1842_15","journal-title":"Indian J Med Res"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-016-1195-7","article-title":"Efficacy and safety of adult human bone marrow-derived, cultured, pooled, allogeneic mesenchymal stromal cells (Stempeucel\u00ae): preclinical and clinical trial in osteoarthritis of the knee joint","volume":"18","author":"Gupta PK","year":"2016","unstructured":"Gupta PK, Chullikana A, Rengasamy M, et al.. Efficacy and safety of adult human bone marrow-derived, cultured, pooled, allogeneic mesenchymal stromal cells (Stempeucel\u00ae): preclinical and clinical trial in osteoarthritis of the knee joint. Arthritis Res Ther. 2016, 18:301. 10.1186\/s13075-016-1195-7","journal-title":"Arthritis Res Ther"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1002\/jeo2.70437","article-title":"Allogenic MSCs are a safe and efficacious treatment for knee osteoarthritis: a systematic review of randomised controlled trials","volume":"12","author":"Loke RY","year":"2025","unstructured":"Loke RY, Chu Z, Liang J, Koh D, Soong J, Lee KH, Razak HR. Allogenic MSCs are a safe and efficacious treatment for knee osteoarthritis: a systematic review of randomised controlled trials. J Exp Orthop. 2025, 12:e70437. 10.1002\/jeo2.70437","journal-title":"J Exp Orthop"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.5312\/wjo.v15.i10.908","article-title":"Evidence-based orthobiologic practice: current evidence review and future directions","volume":"15","author":"Jeyaraman M","year":"2024","unstructured":"Jeyaraman M, Jeyaraman N, Ramasubramanian S, Balaji S, Muthu S. Evidence-based orthobiologic practice: current evidence review and future directions. World J Orthop. 2024, 15:908-17. 10.5312\/wjo.v15.i10.908","journal-title":"World J Orthop"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1186\/s13287-025-04252-2","article-title":"Efficacy and safety of mesenchymal stem cells in knee osteoarthritis: a systematic review and meta-analysis of randomized controlled trials","volume":"16","author":"Cao M","year":"2025","unstructured":"Cao M, Ou Z, Sheng R, et al.. Efficacy and safety of mesenchymal stem cells in knee osteoarthritis: a systematic review and meta-analysis of randomized controlled trials. Stem Cell Res Ther. 2025, 16:122. 10.1186\/s13287-025-04252-2","journal-title":"Stem Cell Res Ther"},{"key":"ref13","unstructured":"Therapeutics - Stempeucel\u00ae. (2022). Accessed. May 27, 2026: https:\/\/www.stempeutics.com\/stempeucel."},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-62544-8","article-title":"Advantages of pooling of human bone marrow-derived mesenchymal stromal cells from different donors versus single-donor MSCs","volume":"14","author":"Kannan S","year":"2024","unstructured":"Kannan S, Gokul Krishna S, Gupta PK, Kolkundkar UK. Advantages of pooling of human bone marrow-derived mesenchymal stromal cells from different donors versus single-donor MSCs. Sci Rep. 2024, 14:12654. 10.1038\/s41598-024-62544-8","journal-title":"Sci Rep"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1002\/jcb.24193","article-title":"Comparative cellular and molecular analyses of pooled bone marrow multipotent mesenchymal stromal cells during continuous passaging and after successive cryopreservation","volume":"113","author":"Mamidi MK","year":"2012","unstructured":"Mamidi MK, Nathan KG, Singh G, et al.. Comparative cellular and molecular analyses of pooled bone marrow multipotent mesenchymal stromal cells during continuous passaging and after successive cryopreservation. J Cell Biochem. 2012, 113:3153-64. 10.1002\/jcb.24193","journal-title":"J Cell Biochem"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1007\/s40258-022-00762-9","article-title":"Cost effectiveness of allogeneic umbilical cord blood-derived mesenchymal stem cells in patients with knee osteoarthritis","volume":"21","author":"Suh K","year":"2023","unstructured":"Suh K, Cole BJ, Gomoll A, et al.. Cost effectiveness of allogeneic umbilical cord blood-derived mesenchymal stem cells in patients with knee osteoarthritis. Appl Health Econ Health Policy. 2023, 21:141-52. 10.1007\/s40258-022-00762-9","journal-title":"Appl Health Econ Health Policy"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.3390\/ph16091334","article-title":"Mesenchymal stem cell therapies approved by regulatory agencies around the world","volume":"16","author":"Fern\u00e1ndez-Garza LE","year":"2023","unstructured":"Fern\u00e1ndez-Garza LE, Barrera-Barrera SA, Barrera-Salda\u00f1a HA. Mesenchymal stem cell therapies approved by regulatory agencies around the world. Pharmaceuticals (Basel). 2023, 16:10.3390\/ph16091334","journal-title":"Pharmaceuticals (Basel)"},{"key":"ref18","unstructured":"JCR receives approval for TEMCELL\u00ae HS Inj., the first allogeneic regenerative medicine in Japan. (2015). Accessed. May 27, 2026: https:\/\/biopharma-asia.com\/sections\/jcr-pharma-launch-temcell-hs-in-japan\/."},{"key":"ref19","unstructured":"TEMCELL\u00ae HS Inj. receives NHI reimbursement price listing. (2015). Accessed. May 27, 2026: https:\/\/www.jcrpharm.co.jp\/en\/assets\/uploads\/docs\/5cd3f9abde84dbc4ec41d141251de007953126c5.pdf."},{"key":"ref20","unstructured":"FDA approves remestemcel-L-rknd for steroid-refractory acute graft-versus-host disease in pediatric patients. (2024). Accessed. May 27, 2026: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-remestemcel-l-rknd-steroid-refractory-acu...."},{"key":"ref21","unstructured":"Mesoblast extends payer coverage for Ryoncil\u00ae to over 100 million US lives. (2025). Accessed. May 27, 2026: https:\/\/investorsmedia.mesoblast.com\/static-files\/1679b15c-b087-4443-8a9b-76c82ba0e39."},{"key":"ref22","unstructured":"Omisirge (omidubicel-onlv). (2026). Accessed. May 27, 2026: https:\/\/www.fda.gov\/vaccines-blood-biologics\/omisirge."},{"key":"ref23","unstructured":"FDA approves cell therapy for patients with blood cancers to reduce risk of infection following stem cell transplantation. (2023). Accessed. May 27, 2026: https:\/\/content.govdelivery.com\/accounts\/USFDA\/bulletins\/3556ad1."},{"key":"ref24","unstructured":"Omisirge\u00ae (omidubicel-onlv) (intravenous), Document Number. IC-0707. (2025). Accessed: May 27, 2026: https:\/\/gatewaypa.com\/api\/policydisplay\/download."},{"key":"ref25","unstructured":"Omisirge. (2025). Accessed. May 27, 2026: https:\/\/resources.massgeneralbrighamhealthplan.org\/medicalpolicy\/Omisirge.pdf."}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/516505-bridging-the-gap-between-regulatory-approval-and-patient-access-the-case-for-insurance-coverage-of-approved-allogeneic-stem-cell-therapy-in-knee-osteoarthritis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T03:33:22Z","timestamp":1787110402000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/516505-bridging-the-gap-between-regulatory-approval-and-patient-access-the-case-for-insurance-coverage-of-approved-allogeneic-stem-cell-therapy-in-knee-osteoarthritis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,18]]},"references-count":25,"URL":"https:\/\/doi.org\/10.7759\/cureus.114764","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8,18]]}}}